about
Temporal lobectomy in early childhood: the need for long-term follow-up.Status epilepticus amauroticus and posterior reversible encephalopathy syndrome in children.De novo FGF12 mutation in 2 patients with neonatal-onset epilepsy.Cerebral sinus thrombosis following IV immunoglobulin therapy of immune thrombocytopenia purpura.Cranial neuropathy, polyneuropathy and thrombocytopenia with Epstein-Barr virus infection.Factors associated with behavioral and cognitive abnormalities in children receiving topiramate.MRI findings in infants with infantile spasms after neonatal hypoxic-ischemic encephalopathy.Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up.Lysine restricted diet for pyridoxine-dependent epilepsy: first evidence and future trials.Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.New antiepileptic drug therapies.Clinical features for prediction of survival in neonatal muscle disease.Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects.Alternating paroxysmal dystonia and hemiplegia in childhood as a symptom of basal ganglia disease.Exome Sequencing and the Management of Neurometabolic Disorders.Pyridoxine responsiveness in novel mutations of the PNPO gene.Systematic review and case series of neuropsychological functioning after epilepsy surgery in children with dysembryoplastic neuroepithelial tumors (DNET).Diagnostic value of a multidisciplinary clinic for intellectual disability.Resective Epilepsy Surgery for Tuberous Sclerosis in Children: Determining Predictors of Seizure Outcomes in a Multicenter Retrospective Cohort Study.De Novo Mutations in YWHAG Cause Early-Onset Epilepsy.Dravet Syndrome: Diagnosis and Long-Term Course.Does treatment have an impact on incidence and risk factors for autism spectrum disorders in children with infantile spasms?Manifestations of Tuberous Sclerosis Complex: The Experience of a Provincial Clinic.Clinical, imaging, and immunohistochemical characteristics of focal cortical dysplasia Type II extratemporal epilepsies in children: analyses of an institutional case series.Outcomes trajectories in children with epilepsy: hypotheses and methodology of a Canadian longitudinal observational study.Clinical Experience With Perampanel for Refractory Pediatric Epilepsy in One Canadian Center.Surgical outcome in tuberous sclerosis complex: a multicenter survey.Loss-of-Function and Gain-of-Function Mutations in KCNQ5 Cause Intellectual Disability or Epileptic Encephalopathy.Spasms in children with definite and probable mitochondrial disease.ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.6-pyruvoyl-tetrahydropterin synthase deficiency with mild hyperphenylalaninemia.Improvement of Self-Injury With Dopamine and Serotonin Replacement Therapy in a Patient With a Hemizygous PAK3 Mutation: A New Therapeutic Strategy for Neuropsychiatric Features of an Intellectual Disability Syndrome.Preserved episodic memory in subcortical band heterotopia.The spectrum of SCN1A-related infantile epileptic encephalopathies.Electroclinical features of absence seizures in sleep.Encephalopathy complicating Henoch-Schönlein purpura: reversible MRI changes.Cingulate lesions presenting with epileptic spasms.Profound neonatal hypoglycemia and lactic acidosis caused by pyridoxine-dependent epilepsy.Rapid cycling in severely multidisabled children: a form of bipolar affective disorder?Hippocampal malrotation and temporal lobe epilepsy: what is the relationship?
P50
Q30658747-4AA44843-90EA-4B67-8CF3-79F4459D4F31Q30659096-1C10FE19-2D2E-4067-AC57-A580DCD31646Q30828995-3A5C1F08-C9FB-4A84-97CB-A8AE90AECDDBQ33394682-6B055754-1850-469C-9B82-A1936BE981DDQ33491171-036CA477-A1A0-4994-993A-85DDA3252126Q33873526-ED5FA603-3BB9-4281-96E3-6B39251899B2Q33982452-3ABF7869-FAEB-4788-827B-E2C0C0924BC4Q34195320-C91567CC-0042-4949-B4CE-1C55C077258EQ34302609-7A9F630F-8BFF-4546-A538-AE510C3E47CCQ34408357-2ECCE289-F6D9-4CCC-B5A7-BBCE07A3C176Q35077748-4D2244FF-90DF-4440-AF00-DB59A5068401Q35352267-E685FD2B-A159-4DC6-9003-1A834EFDCFE0Q36505021-B87E151A-B2D1-43B8-98DE-0D9A7656CEECQ36883099-5E0F7F91-268E-4FF7-A5B6-C521FC9F4175Q37171865-2588138D-30CE-45F4-8436-41E312920E43Q37725884-FFC39F59-63AC-4C9F-9DDB-1313543C3F3FQ37990240-452C0909-026E-440D-9F72-64B21B3CB7B0Q38203460-4663BC91-6011-46A9-ACF1-56F73BDB201DQ38539777-94181BBD-7633-4A8D-8A20-00DC352CDE01Q38640554-71C4B2F1-6F6F-4171-9203-6E6CADADE16EQ38855478-91A6CAB4-C2F8-40A3-A35D-6D89663849F9Q39010547-59B73D63-3286-47B3-9D19-0571B8BE5015Q39048621-44E3EAEB-BD65-43D6-A022-2761D111EAFBQ39154800-38A3A8C0-D0FA-4E77-BFF7-428A5F08260AQ39287780-9CE79507-D46E-4A2D-A3DF-BCE036829EAFQ39311787-DEBCADF5-3691-448C-B44E-2AE368C94F41Q39335708-A9026F04-712F-4B0B-B2BE-6685CEA03F85Q42428340-64F95DBD-A08A-4D86-A1A3-8DBF64D70203Q44746052-C13671A9-86EC-4AE5-829D-3F5676D38AA3Q46206411-EE011A51-4091-4088-BEFF-3705A5AD039FQ46571369-722901EA-CABF-44E2-8F67-F70A0AA01242Q47274476-4F2AA408-DFFB-4F5A-9080-78D61330F682Q47722637-FE806230-E297-4C7D-84A6-A7679235FF4AQ48249670-0B734322-D6AC-4C27-9906-70AD07680DE0Q48320415-22655896-D334-435A-A819-76DE63EF5674Q48421733-A15CA929-1293-4C14-BEE5-B379F11D1044Q48459437-8525DBF7-E330-4CC2-A00B-FC6EBC84BFA0Q48551596-0BD20D01-D637-4044-9F0E-614075E1FEB0Q48851366-2A048CA6-EAA3-4B7C-936B-00B9998CFB80Q49126683-FBA8A46F-488C-4EC6-8BEF-6593ABB7A2CC
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mary B Connolly
@ast
Mary B Connolly
@en
Mary B Connolly
@es
Mary B Connolly
@nl
Mary B Connolly
@sl
type
label
Mary B Connolly
@ast
Mary B Connolly
@en
Mary B Connolly
@es
Mary B Connolly
@nl
Mary B Connolly
@sl
prefLabel
Mary B Connolly
@ast
Mary B Connolly
@en
Mary B Connolly
@es
Mary B Connolly
@nl
Mary B Connolly
@sl
P106
P21
P31
P496
0000-0002-7784-942X